Financings
MustGrow Closes $3.7 Million Non-Brokered LIFE Offering
MustGrow Biologics Raises $3.7M to Fund TerraSante Biofertility Ramp Amid Persistent Cash Burn
Executive Summary
- MustGrow Biologics Corp. closed a non-brokered private placement (LIFE Offering) on June 19, 2026.
- Gross proceeds of approximately $3.74 million were raised by issuing 7,481,541 units at $0.50 per unit.
- Each unit comprises one common share and one common share purchase warrant exercisable for 60 months at $0.70 per share.
- Net proceeds are allocated to inventory production for the flagship TerraSante™ biofertility product, working capital, and general corporate purposes.
- Finder compensation was set at 6.0% in cash fees plus 6.0% in non-transferable warrants.
- The offering was conducted under the Listed Issuer Financing exemption (NI 45-106 Part 5A) and is subject to TSXV approval.
- Capital structure context indicates ~70.4 million common shares outstanding prior to the offering, expanding to ~91.9 million on a fully diluted basis.
Material Impact
- The financing directly addresses the company's severe liquidity constraints. Q1 2026 financials revealed only $0.42 million in cash and equivalents, with operating cash burn exceeding $2.28 million in the quarter.
- The $3.74 million injection provides approximately 18 months of runway, assuming continued operational scaling and no major cost overruns.
- The offering price of $0.50 is at a slight premium to the recent trading range ($0.44-$0.49), but the issuance of new shares and warrants introduces significant dilution. Fully diluted shares will increase by roughly 26%.
- The use of proceeds aligns with management's stated pivot to commercialize TerraSante™ in the U.S., but does not alter the fundamental cash-burn profile of the business.
- The market impact is expected to be neutral to slightly negative in the short term due to dilution, but the capital injection mitigates immediate bankruptcy risk.
MGRO · Price
Company Overview
- MustGrow Biologics Corp. is an agricultural biologics company focused on developing and commercializing plant-based products.
- Flagship product: TerraSante™, a mustard-derived organic biofertility product designed to improve soil microbiome health, nutrient/water use efficiency, and crop yields.
- Pipeline product: TerraMG™, a biocontrol product targeting clubroot disease in canola, currently undergoing field trials and regulatory review in Canada.
- The company previously operated a Canadian distribution arm, NexusBioAg, which has been wound down to focus resources on U.S. TerraSante™ sales.
- The business model relies on third-party contract manufacturing and direct sales to U.S. farmers and retailers, with international expansion plans via partnerships like Bayer AG for EMEA.
More from MustGrow Biologics Corp.
Jun 17, 2026 · 19:22